Skip to content

Study · Randomized controlled trial · n = 30 · 2022

7 results

Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease.

Xiao Y, Liu Y, Zhao L, Zhou Y

Metabolic syndrome and related disorders4 Aug 2022Cited by 24 (Europe PMC)

PMID35925752 (opens in a new tab)DOI10.1089/met.2022.0014 (opens in a new tab)PepBankPUB-35925752
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, liraglutide 1.8 mg/day decreased CAP (liver fat) by 5.5% from baseline at 24 weeks.

    In plain wordsIn people with type 2 diabetes and fatty liver, liraglutide lowered a measure of liver fat after 24 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseControlled attenuation parameter (CAP) change at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Measurements

    CAP decrease
    5.5%
    Lira group

    Source sentences

    Summary
    At 24 weeks after intervention, compared with those at baseline, CAP was significantly decreased in both the 5:2 diet group and Lira group, which was 7.4% and 5.5%, respectively.
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, body weight improved significantly from baseline with liraglutide at 24 weeks (P < 0.05).

    In plain wordsIn people with type 2 diabetes and fatty liver, body weight improved after 24 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBody weight at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight, plasma lipids and glucose profile, and liver function parameters improved significantly, while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all P < 0.05).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, plasma lipids improved significantly from baseline with liraglutide at 24 weeks (P < 0.05).

    In plain wordsIn people with type 2 diabetes and fatty liver, blood fat levels improved after 24 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedPlasma lipids at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight, plasma lipids and glucose profile, and liver function parameters improved significantly, while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all P < 0.05).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, the glucose profile improved significantly from baseline with liraglutide at 24 weeks (P < 0.05).

    In plain wordsIn people with type 2 diabetes and fatty liver, blood sugar measures improved after 24 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlucose profile at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight, plasma lipids and glucose profile, and liver function parameters improved significantly, while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all P < 0.05).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, liver function parameters improved significantly from baseline with liraglutide at 24 weeks (P < 0.05).

    In plain wordsIn people with type 2 diabetes and fatty liver, liver function tests improved after 24 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedLiver function parameters at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight, plasma lipids and glucose profile, and liver function parameters improved significantly, while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all P < 0.05).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, HOMA-beta increased significantly from baseline with liraglutide at 24 weeks (P < 0.05).

    In plain wordsIn people with type 2 diabetes and fatty liver, a measure of beta-cell function rose after 24 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseHOMA-beta at 24 weeks
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all P < 0.05).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).
  7. 07HumanRandomized controlled trialMechanism

    In patients with type 2 diabetes and NAFLD on liraglutide, increased HOMA-beta and SOD and reduced BMI were independent predictors of the CAP decrease.

    In plain wordsIn people with type 2 diabetes and fatty liver on liraglutide, better beta-cell function, more antioxidant and lower BMI went with less liver fat.

    Peptide
    Liraglutide
    Outcome
    Not applicablePredictors of CAP decrease in the Lira group
    Study

    n = 30

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    1.8 mg/day · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Stepwise linear regression showed that increased HOMA-β and SOD, as well as reduced body mass index (BMI), were the independent predictors of CAP decrease in the Lira group (P = 0.000, 0.000, 0.015).
    1 context sentence
    Summary · context
    Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, n = 31) and 1.8 mg/day liraglutide intervention group (Lira group, n = 30).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.